Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral
Pneumagen's intranasal broad-spectrum antiviral therapy reduced infection, improved symptoms and severity and reduced viral load in a Phase II influenza study in data published in the high-impact, peer-reviewed Infectious Diseases and Therapy journal. St Andrews, UK – 2 July 2025 – Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug […]